Objective: We investigated the effects of polymorphisms of OCM associated genes and their interactions on the survival of GC patients receiving 5-FU-based regimens, including (MTHFR1298AC, 677CT), (MTRR66AG), (5'-UTR2R3R TS, 3'UTRins6del6) and (MTR 2756AG).
Methods: A total of 297 chemotherapy patients and other 622 patients were recruited. The Cox regression analyses, log-rank tests and Kaplan-Meier plots were adopted.
Results: MTRR 66GA+GG and MTHFR1298CA+CC genotypes decreased death risk (HR =0.668, 95% CI =0.470-0.949, HR =0.628, 95% CI =0.422-0.935, respectively) but TS5'-UTR2R3R+2R2R genotypes increased death risk (HR =1.606, 95% CI =1.121-2.301). The favorable prognosis improved when GC patients simultaneously had MTHFR1298 CA+CC and MTRR66GG+GA (HR =0.520, 95% CI =0.285-0.947). Although MTHFR677TT+TC were not related with the prognosis of GC patients, the poorer prognosis obviously enhanced when patients simultaneously had TS5-UTR2R2R+2R3R and MTHFR677TT+TC (HR =2.152, 95% CI =1.219-3.798).
Conclusions: In all, polymorphisms of MTHFR1298AC TS5-UTR 3R2R and MTRR66AG may be biomarkers for patients receiving 5-FU regimens.
